Bill Griffiths joins NDA group as general manager UK
pharmafile | March 2, 2016 | Appointment | Medical Communications | NDA Group
Industry veteran Bill Griffiths has joined NDA Group to head up the company’s UK consulting team and NDA’s advisory board. Griffiths brings extensive international pharmaceutical experience, having previously held senior positions within Abbott, GSK, Pfizer and Solvay Pharmaceuticals. He joined NDA March 1, 2016.
As the new general manager for the company’s UK team, Griffiths will be responsible for managing and driving all the UK business for NDA group. This encompasses regulatory, pharmacovigilance and HTA consultancy for regional and global pharma, from small biotech, through to top 20 large pharma companies. The UK operation, based in London, is supported by a team of close to 50 consultants and support staff.
“The UK consulting team is NDA’s largest team and one of the most important business units for NDA,” says Johan Strömquist, chief executive, NDA group. “Identifying an individual with the right background, skillset and experience to support our experienced team and client base has been a challenge. I’m therefore delighted to bring Bill on board. He brings a fantastic background with both strong pharmaceutical expertise, coupled with outstanding team management – key criteria for driving our UK operations forward.”
In addition to his role as UK GM, Griffiths will take on the responsibilities of vice president of NDA’s advisory services. Within this role, Bill will manage the operations, strategy and development of the advisory board, including business development, sales, marketing and service development.
Griffiths will be closely supported by Steffen Thirstrup, Director NDA Regulatory Advisory Board, and Markku Toivonen, NDA Scientific Director, the company says.
Pharmaceutical expertise
Griffiths joins NDA from Abbott, where he was divisional vice president of Global Regulatory Affairs, based in Basel. In this role, he led the regulatory function comprising five geographic teams (Europe, Latin America, Asia Pacific, India, Japan), three functional teams (Quality Systems, Labelling & Ad Promo, Policy & Intelligence) and a specialist Influenza vaccines team. He had direct leadership of 180 staff and managed a portfolio of more than 8,000 product licenses across 130 markets worldwide. Prior to this, Griffiths was senior vice president, Global Regulatory Operations, at Solvay Pharmaceuticals, a role he held for six years.
Griffiths has additionally run his own consultancy – Team Pharma Consulting for three years, as well as spending 15 years within Glaxo in various senior roles.
Related Content
Free webinar – Rational EU risk management for oncology medicines
It is timely to reflect on how we can best implement the revised GVP module …
NDA Group and PharmApprove announce merger
NDA Group, a leading strategic regulatory and HTA consultancy in Europe, and PharmApprove, a leading …
EMA’s Thomas Lönngren joins market access firm
The former head of the EMA Thomas Lönngren has taken up a post at new …
